Novo Nordisk posts strong sales and earnings growth for year to date

3 November 2021
novo_nordisk_copenhagen_large

Denmark-based diabetes care giant Novo Nordisk (NOV: N) today reported financial results, showing that n the first nine months of 2021 operating profit was 45.01 billion Danish kroner ($5.34 billion), an increase of 5% in kroner terms and up 12% at constant exchange rates (CER).

Net profit was up 12% at 36.87 million kroner, with diluted earnings per share of 15.98 kroner, a rise of 14%. Novo Nordisk’s shares were up 2.75% at 112.80 kroner pre-market.

Sales increased by 8% in kroner and by 13% at CER to 102.47 billion kroner. Sales in International Operations increased by 10% in kroner (13% at CER), and sales in North America Operations increased by 6% in kroner (13% at CER). Sales in the third quarter of 35.62 billion increased 15% in kroner (15% at CER) compared to the third quarter of 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical